- Global Pharma News & Resources

Worldwide RNA Analysis Industry to 2027 - Rising RNA Analysis in Cancer Personalized or Precision Medicine is Driving Growth -

DUBLIN--(BUSINESS WIRE)--The "RNA Analysis Market- Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)" report has been added to's offering.

The RNS analysis market is projected to register a CAGR of 13.6% during the forecast period (2022-2027).

Companies Mentioned

  • Thermo Fisher Scientific
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc
  • Eurofins Scientific
  • Merck KGaA
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc
  • Bio-Rad Laboratories, Inc.
  • Promega Corporation
  • GenXPro GmbH
  • LC Sciences

Key Market Trends

The Reagents/Consumables Segment is Expected to Hold a Major Market Share in the RNA Analysis Market

The demand for detection and diagnosis is predicted to rise during the COVID epidemic, boosting the segment's growth. During the forecast period, the increased prevalence of infectious diseases and oncological occurrences are also expected to boost segmental growth.

The demand for high-quality reagents is growing, as is the usage of medium and reagents in transcriptome investigations. The pharmaceutical industry's increased R&D efforts, government spending on life science research, and the growing research being done with integrated omics studies are all contributing to the consumables market.

According to the American Cancer Society, In 2020, the treatment and diagnosis of cancer were reduced and disturbed by the COVID-19 pandemic. For instance, lockdown restricted access to care and delayed diagnosis and treatment, which are expected to slow down the detection and diagnosis of cancer incidence, but the advanced stage infectious disease increased mortality.

According to World Health Organization-WHO, cancer is one of the main reason of death worldwide; about 10 million deaths were noted in 2020, which was 1 in 6 deaths. According to World Health Organization-WHO 2020, Cancer-causing infections, such as human papillomavirus (HPV) and hepatitis, are responsible for approximately 30% of cancer cases in low- and lower-middle-income countries.

Thus, the increasing prevalence of cancer and infectious diseases such as COVID-19 demanded a high diagnostic rate in medical specialties and diagnostic care centers and thus expected to propel the segmental growth during the forecast period.

The growing prevalence of chronic diseases, rising number of hospital admissions due to infectious diseases, and increasing healthcare expenditures are the factors supporting and expected to accelerate the growth and demand for Regents / Consumables and drive the market growth. COVID -19 has accelerated the consumption of the regents/consumables in various end users such as hospitals and diagnostic centers. The growing penetration of consumables also propels the growth of the segment in the market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global RNA analysis market due to the increasing prevalence and incidence of cancer and infectious diseases in this region. In 2019, North America held a major market share for RNA analysis, and this trend would remain in the forecast period as well.

According to the American Cancer Society, about 1.9 million cases were found in the United States suffering from Cancer, and 608,570 deaths were notified in the year 2021. The American Cancer Society also states that a 2021 special section was arranged to focus more on the population suffering from COVID-19 and Cancer together and the overall American healthcare system. Moreover, the increase in such activities and the presence of favorable healthcare infrastructure are fueling the growth of the overall regional market to a large extent.

The market in the region is boosted by rising demand for various assay technologies, quantification of multiplexed RNA, increased need for genetic testing and personalized treatment, and an increase in genetic variation and genetic mutation occurrences. Because of the vast number of biotech companies with well-established infrastructure and cutting-edge technical platforms, North America is the most prominent region.

Other factors driving market expansion include expanding opportunities, rising healthcare expenditures, and the implementation of government programs. The commercial sector's continued investment in transcriptomics-related research and development is allowing regional market players to produce tailored medicines.

Key Topics Covered:





4.1 Market Overview

4.2 Market Drivers

4.2.1 Rising RNA Analysis in Cancer Personalized or Precision Medicine

4.2.2 Growing Applications of RNA Sequencing in Transcriptomics

4.3 Market Restraints

4.3.1 High Cost Associated With Platforms

4.3.2 High Capital Investments for Research and Development

4.4 Porter's Five Forces Analysis


5.1 By Product Type

5.2 By Technology

5.3 By Application

5.4 By End User

5.5 Geography


6.1 Company Profiles

6.1.1 Thermo Fisher Scientific

6.1.2 F. Hoffmann-La Roche Ltd

6.1.3 Illumina, Inc

6.1.4 QIAGEN

6.1.5 Eurofins Scientific

6.1.6 Merck KGaA

6.1.7 Bio-Rad Laboratories, Inc.

6.1.8 Agilent Technologies, Inc

6.1.9 Bio-Rad Laboratories, Inc.

6.1.10 Promega Corporation

6.1.11 GenXPro GmbH


6.1.13 LC Sciences


For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 09-Dec-2022